Afadin cooperates with Claudin-2 to promote breast cancer metastasis

  1. Peter M. Siegel1,2,3
  1. 1Goodman Cancer Research Centre, McGill University, Montréal, Québec H3A 1A3, Canada;
  2. 2Department of Medicine, McGill University, Montréal, Québec H3A 1A3, Canada;
  3. 3Department of Biochemistry, McGill University, Montréal, Québec H3A 1A3, Canada;
  4. 4Institut du Cancer de Montréal, Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montréal, Québec H2X 0A9, Canada;
  5. 5Department of Pathology, McGill University Health Centre, Montréal, Québec H4A 3J1, Canada;
  6. 6Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60614, USA;
  7. 7Stanley Manne Children's Research Institute, Chicago, Illinois 60614, USA;
  8. 8Department of Human Genetics, McGill University, Montréal, Québec H3A 1A3, Canada;
  9. 9Division of Oncology, Department of Clinical Sciences, Lund University, Lund SE 221 00, Sweden
  1. Corresponding author: peter.siegel{at}mcgill.ca

Abstract

Claudin-2 promotes breast cancer liver metastasis by enabling seeding and early cancer cell survival. We now demonstrate that the PDZ-binding motif of Claudin-2 is necessary for anchorage-independent growth of cancer cells and is required for liver metastasis. Several PDZ domain-containing proteins were identified that interact with the PDZ-binding motif of Claudin-2 in liver metastatic breast cancer cells, including Afadin, Arhgap21, Pdlim2, Pdlim7, Rims2, Scrib, and ZO-1. We specifically examined the role of Afadin as a potential Claudin-2-interacting partner that promotes breast cancer liver metastasis. Afadin associates with Claudin-2, an interaction that requires the PDZ-binding motif of Claudin-2. Loss of Afadin also impairs the ability of breast cancer cells to form colonies in soft agar and metastasize to the lungs or liver. Immunohistochemical analysis of Claudin-2 and/or Afadin expression in 206 metastatic breast cancer tumors revealed that high levels of both Claudin-2 and Afadin in primary tumors were associated with poor disease-specific survival, relapse-free survival, lung-specific relapse, and liver-specific relapse. Our findings indicate that signaling downstream from a Claudin-2/Afadin complex enables the efficient formation of breast cancer metastases. Moreover, combining Claudin-2 and Afadin as prognostic markers better predicts the potential of breast cancer to metastasize to soft tissues.

Keywords

Footnotes

  • Supplemental material is available for this article.

  • Article published online ahead of print. Article and publication date are online at http://www.genesdev.org/cgi/doi/10.1101/gad.319194.118.

  • Freely available online through the Genes & Development Open Access option.

  • Received July 22, 2018.
  • Accepted November 19, 2018.

This article, published in Genes & Development, is available under a Creative Commons License (Attribution 4.0 International), as described at http://creativecommons.org/licenses/by/4.0/.

| Table of Contents
OPEN ACCESS ARTICLE

Life Science Alliance